Skip to content
lifestyle.ubi-interactive.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Erasca, Inc.
Erasca to Present at the Jefferies Global Healthcare Conference
May 27, 2026
Erasca Reports First Quarter 2026 Business Updates and Financial Results
May 24, 2026
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)
May 23, 2026
Erasca to Present at the Bank of America Securities Health Care Conference
May 22, 2026
Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
May 21, 2026
Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015
May 20, 2026
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results
March 12, 2026
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau
March 10, 2026
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat
March 5, 2026
Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001
February 24, 2026
1
2
Next Page
→